Melbourne, Australia and Atlanta, Georgia, 28 April 2014: Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM). The exclusive agreement enables STA to distribute
![Arctica Specialised Therapeutics](https://stabiopharma.com/wp-content/uploads/2021/03/stabio-logo.png)